These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 20051682)
1. Which role for rituximab in hairy cell leukemia? Reflections on six cases. Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682 [TBL] [Abstract][Full Text] [Related]
2. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250 [TBL] [Abstract][Full Text] [Related]
3. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063 [TBL] [Abstract][Full Text] [Related]
4. Hairy cell leukemia: current concepts. Cannon T; Mobarek D; Wegge J; Tabbara IA Cancer Invest; 2008 Oct; 26(8):860-5. PubMed ID: 18798068 [TBL] [Abstract][Full Text] [Related]
5. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389 [TBL] [Abstract][Full Text] [Related]
6. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889 [TBL] [Abstract][Full Text] [Related]
7. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin]. Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434 [TBL] [Abstract][Full Text] [Related]
8. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Robak T Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083 [TBL] [Abstract][Full Text] [Related]
9. Cladribine in hairy cell leukemia. Belani R; Saven A Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111 [TBL] [Abstract][Full Text] [Related]
10. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy]. Rucińska M; Machaczka M; Załuska A; Skotnicki AB Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Hensel M; Ho AD Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118 [TBL] [Abstract][Full Text] [Related]
12. Treatment of hairy-cell leukemia: current views. Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049 [TBL] [Abstract][Full Text] [Related]
14. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328 [TBL] [Abstract][Full Text] [Related]
15. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126 [TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine. Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866 [TBL] [Abstract][Full Text] [Related]
17. Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410 [TBL] [Abstract][Full Text] [Related]